AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative ColitisPRNewsWire • 05/31/24
AbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with New Data from Its Innovative Antibody-Drug Conjugate (ADC) PlatformPRNewsWire • 05/28/24
High Yields And Low Multiples - 3 Of My Favorite Dividend Stocks To Buy Right NowSeeking Alpha • 05/24/24
1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165?The Motley Fool • 05/20/24
AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week®PRNewsWire • 05/17/24
Wall Street Favorites: 3 Retirement Stocks With Strong Buy Ratings for May 2024InvestorPlace • 05/16/24